Stanley Capital Partners-backed Laboratoire X.O acquires an anaesthetic prescription product from a US-based company

21 December 2022, London – Laboratoire X.O (Lab XO), a portfolio company of Stanley Capital Partners (SCP), announces the acquisition of a local anaesthetic used by ENT (Ear, Nose & Throat) surgeons when performing procedures and surgeries on or through the nasal cavities in adults. The product, sold in the US market, is available in a unit dose to be applied to the patient prior to surgery.

This acquisition further strengthens the presence of the group in the US and supports the continued diversification of its product portfolio under SCP’s ownership by entering a new therapeutic area in anaesthesia.


Karine Pinon, CEO of Lab XO:

This product is Laboratoire X.O’s 19th add-on acquisition since its inception in 2015, adding to our track record of successfully integrating products into our platform. We are utilising our expanded footprint by integrating this product into our new Dublin hub and leveraging the team’s expertise in the US market.

Simon Cottle, Founding Partner of Stanley Capital Partners:

With this acquisition, we continue to demonstrate Laboratoire X.O’s ability to attract and integrate new products into the platform.

Patrick Hargutt, Founding Partner of Stanley Capital Partners:

The transaction also serves our strategic objectives of further diversifying the platform, both from a product offering and market presence perspective.

About Stanley Capital Partners LLP

Stanley Capital Partners LLP (SCP) is a fast-growing European-focused mid-market private equity firm with proven expertise in finding and building value, locked up in the growth businesses of tomorrow. The firm brings enhanced efficiency through proprietary research and technology to identify investment opportunities that help deliver lasting transformation in Healthcare, Technology and Resource Efficiency businesses with enterprise values of $250m-2.5bn or more. Founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt, SCP partners with management teams to create value through M&A, operational change, and technology enablement. With a 100+-strong team of professionals, SCP has assets under management of $460m today.

Find out more at


About Laboratoire X.O

Founded in 2015, Laboratoire X.O (Lab XO) is a French pharmaceutical company that operates a range of mostly non-generic prescription medicines in France and internationally. Lab XO focuses on brand-name drugs for the treatment of chronic diseases, with proven efficacy and safety and strong brand awareness. Since its creation, Lab XO has made numerous acquisitions to broaden its product portfolio and its range of expertise. Today, the business brings together teams with expertise in quality management, regulatory issues, logistics/distribution, marketing, and sales. Lab XO operates as an agile platform, outsourcing all production to leading subcontractors in Europe. The company is committed to being as close as possible to the needs of healthcare professionals and patients for its medicines, medical devices and cosmetics. Lab XO’s growth is fuelled by the success of its brands, its international expansion, and its external acquisition strategy. The business has a turnover of over €80m and a distribution network of more than 45 countries (Europe, the US, the Maghreb, and the Francophone world).

Find out more at